NICE recommends Yervoy (BMS) and Zelboraf (Roche) for Melanoma
NICE, The National Institute of Health and Clinical Excellence, has provided final and binding guidance that recommends both Yervoy (ipilimumab) from BMS and Zelboraf (vemurafenib) from Roche, for melanoma patients. Both recommendations were conditioned on a discount offered under a patient access scheme. Yervoy is recommended for the treatment of advanced Malignant Melanoma in people who have received prior chemotherapy and Zelboraf is recommended for the treatment of unresectable locally advanced or Metastatic BRAF V600 mutation-positive Melanoma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.